About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5317865
Allelic
Composition
Tg(KRT5-rtTA)1Glk/0
Tg(tetO/CMV-Tslp)#Sfz/0
Genetic
Background
involves: C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including hyperkeratosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis (J:100506)
• by 5 weeks of dox treatment, lesional skin shows characteristic changes of eczematous inflammation including acanthosis (J:100506)
• majority of dox treated mice exhibit a mild xerosis (J:100506)
• majority of dox treated mice exhibit a mild xerosis (J:100506)
• seen in dox treated mutants (J:100506)
• seen in dox treated mutants (J:100506)
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment (J:100506)
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back (J:100506)
• less commonly, lesions are seen on the anterior neck and hind legs (J:100506)
• dox treated mutants exhibit skin lesions consisting of mild erythema at 2 weeks of dox treatment with progression to eczematous-like changes, including erythema, crusting, and erosions, by 3-4 weeks of dox treatment (J:100506)
• skin lesions are most common on the snout, postauricular region, nape of the neck and upper back (J:100506)
• less commonly, lesions are seen on the anterior neck and hind legs (J:100506)

immune system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes (J:100506)
• dox treated mutants exhibit a 14-fold increase in IL-4 producing cells in the skin-draining lymph nodes and an 18-fold increase in the intestinal mesenteric lymph nodes (J:100506)
• dox treated mutants exhibit lymphadenopathy (J:100506)
• dox treated mutants exhibit lymphadenopathy (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)
• mutants treated with doxycycline (dox) to induce expression of Tslp develop skin disease beginning at about 2-3 weeks of dox treatment (J:100506)
• dox treated mutants exhibit dermal infiltrates containing lymphocytes, macrophages, mast cells, and eosinophils (J:100506)
• however, inflammation is not seen in the small intestine or colon (J:100506)

hematopoietic system
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit an increase in the frequency of and absolute numbers of IL-4 producing Th2 CD4+ T cells in both the spleens and lymph nodes (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• dox treated mutants exhibit splenomegaly (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)
• in dox treated mutants (J:100506)

homeostasis/metabolism
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• by 5 weeks of doxycycline (dox) treatment, lesional skin shows characteristic changes of eczematous inflammation including spongiosis (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)
• dox treated mutants exhibit an increase in Th2 cytokines in effected skin (J:100506)

vision/eye
• a few dox treated mice exhibit conjunctivitis (J:100506)
• a few dox treated mice exhibit conjunctivitis (J:100506)

Mouse Models of Human Disease
OMIM ID Ref(s)
Dermatitis, Atopic 603165 J:100506


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/02/2016
MGI 6.02
The Jackson Laboratory